It is known that EGFR-mutant NSCLC is generally associated with a more indolent disease course since over 85% EGFR mutant NSCLC respond to TKIs, even if it is only for a prescribed and limited period of time [41]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.